Danicopan therapy with eculizumab or ravulizumab may reduce breakthrough hemolysis events in PNH patients: Study Dr Riya Dave19 Dec 2024 8:30 AM ISTResearchers have discovered that with the dual inhibition of C5 and factor D, patients with paroxysmal nocturnal hemoglobinuria (PNH) develop fewer...
Switching from eculizumab to ravulizumab safely preserves renal function in atypical hemolytic uremic syndrome: Study Dr. Shravani Dali25 July 2024 8:00 PM ISTSwitching from eculizumab to ravulizumab safely preserves renal function in atypical hemolytic uremic syndrome suggests a study published in the BMC...
AstraZeneca Voydeya approved in EU as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia Ruchika Sharma26 April 2024 4:10 PM ISTAstraZeneca has announced that Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or...
USFDA nod to Voydeya as add on therapy to ravulizumab or eculizumab for extravascular haemolysis in adults with rare disease PNH: AstraZeneca Ruchika Sharma1 April 2024 3:18 PM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the...
AstraZeneca blood disorder drug recommended for EU nod Ruchika Sharma27 Feb 2024 11:29 AM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an...
Ravulizumab lacks treatment effect, highlights unmet need for highly effective treatment for ALS Medha Baranwal18 Nov 2023 9:30 AM ISTUSA: A recent study published in JAMA Neurology investigated the safety and efficacy of ravulizumab, a complement C5 inhibitor, in adults with...
AstraZeneca Ultomiris gets Japanese nod for prevention of relapses in patients with neuromyelitis optica spectrum disorder Ruchika Sharma28 May 2023 11:00 AM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
AtraZeneca's Ultomiris approved in EU for adults with neuromyelitis optica spectrum disorder Ruchika Sharma12 May 2023 1:30 PM ISTNeuromyelitis optica spectrum disorder is a rare and debilitating autoimmune disease that affects the central nervous system including the spine and...
AstraZeneca Ultomiris recommended for marketing approval in EU for neuromyelitis optica spectrum disorder Ruchika Sharma4 April 2023 4:00 PM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
AstraZeneca Ultomiris approved in Europe for treatment of adults with generalised myasthenia gravis Ruchika Sharma25 Sept 2022 12:00 PM ISTUltomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete and sustained complement inhibition.
AstraZeneca gets Japenese nod for Ultomiris to treat generalised myasthenia gravis Ruchika Sharma29 Aug 2022 9:30 AM ISTgMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness.
Ravulizumab effective treatment option for Generalized Myasthenia Gravis Dr. Shravani Dali3 Jun 2022 9:30 PM ISTRavulizumab demonstrated rapid and sustained improvements in both patient- and clinician-reported outcomes in Generalized myasthenia gravis (gMG),...
